A. Nesterova

发表

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven, Y. Hotko, H. Denys, 2023, Cancer Research.

Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus

A. Kedrova, E. Shakhnovich, A. Goryainova, 2023, Tumors of female reproductive system.

Unravelling the Therapeutic Potential of Antibiotics in Hypoxia in a Breast Cancer MCF-7 Cell Line Model

R. Miftakhova, A. Rizvanov, Sjoerd Wanrooij, 2023, International journal of molecular sciences.

Cancer of unknown primary and the «seed and soil» hypothesis.

L. A. Mingazova, Yuliya V. Filina, A. Nesterova, 2024, Critical Reviews in Oncology/Hematology.